Literature DB >> 21343400

Discovery of DNA repair inhibitors by combinatorial library profiling.

Benjamin J Moeller1, Richard L Sidman, Renata Pasqualini, Wadih Arap.   

Abstract

Small molecule inhibitors of DNA repair are emerging as potent and selective anticancer therapies, but the sheer magnitude of the protein networks involved in DNA repair processes poses obstacles to discovery of effective candidate drugs. To address this challenge, we used a subtractive combinatorial selection approach to identify a panel of peptide ligands that bind DNA repair complexes. Supporting the concept that these ligands have therapeutic potential, we show that one selected peptide specifically binds and noncompetitively inactivates DNA-PKcs, a protein kinase critical in double-strand DNA break repair. In doing so, this ligand sensitizes BRCA-deficient tumor cells to genotoxic therapy. Our findings establish a platform for large-scale parallel screening for ligand-directed DNA repair inhibitors, with immediate applicability to cancer therapy. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343400      PMCID: PMC3057608          DOI: 10.1158/0008-5472.CAN-10-2361

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Alternative pathways for the repair of RAG-induced DNA breaks.

Authors:  David M Weinstock; Maria Jasin
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

2.  Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair.

Authors:  Laura Spagnolo; Angel Rivera-Calzada; Laurence H Pearl; Oscar Llorca
Journal:  Mol Cell       Date:  2006-05-19       Impact factor: 17.970

Review 3.  Trojan peptides: the penetratin system for intracellular delivery.

Authors:  D Derossi; G Chassaing; A Prochiantz
Journal:  Trends Cell Biol       Date:  1998-02       Impact factor: 20.808

4.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Authors:  Richard D Kennedy; Clark C Chen; Patricia Stuckert; Elyse M Archila; Michelle A De la Vega; Lisa A Moreau; Akiko Shimamura; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

5.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

Authors:  W Arap; R Pasqualini; E Ruoslahti
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

6.  Analysis of DNA repair and chromatin assembly in vitro using immobilized damaged DNA substrates.

Authors:  Jill A Mello; Jonathan G Moggs; Geneviève Almouzni
Journal:  Methods Mol Biol       Date:  2006

7.  ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

Authors:  Shuhei Matsuoka; Bryan A Ballif; Agata Smogorzewska; E Robert McDonald; Kristen E Hurov; Ji Luo; Corey E Bakalarski; Zhenming Zhao; Nicole Solimini; Yaniv Lerenthal; Yosef Shiloh; Steven P Gygi; Stephen J Elledge
Journal:  Science       Date:  2007-05-25       Impact factor: 47.728

Review 8.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

9.  Resistance to therapy caused by intragenic deletion in BRCA2.

Authors:  Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

10.  A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.

Authors:  Christopher J Lord; Sarah McDonald; Sally Swift; Nicholas C Turner; Alan Ashworth
Journal:  DNA Repair (Amst)       Date:  2008-10-15
View more
  2 in total

1.  DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Authors:  Euan A Stronach; Michelle Chen; Elaina N Maginn; Roshan Agarwal; Gordon B Mills; Harpreet Wasan; Hani Gabra
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

Review 2.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.